CardioNXT

CardioNXT is a US-based, private medical device company founded in 2015, specializing in 3D mapping and navigation systems for cardiac ablation procedures. Its core iMap System platform is FDA 510(k) cleared and is being developed to navigate novel pulsed field ablation (PFA) catheters from major players like Boston Scientific and Medtronic, as well as its own sensor-enabled diagnostic catheters. The company is led by a seasoned team with prior successful exits in the medical device space, including the co-founder of Veran Medical Technologies (acquired by Olympus). CardioNXT operates in the high-growth cardiac ablation market, positioning itself as an enabling navigation platform for the next wave of PFA technologies.

The CardioNXT iMap System is an electromagnetically-based 3D mapping and navigation platform for cardiac electrophysiology procedures. It enables zero-fluoroscopy navigation, electromagnetic field scaling, and features custom software interfaces designed specifically to integrate with and navigate next-generation pulsed field ablation (PFA) catheters from various manufacturers.

CardioNXT competes in the cardiac EP mapping market, which is dominated by large players like Johnson & Johnson (Biosense Webster CARTO) and Abbott (EnSite Precision) that offer integrated mapping and ablation systems. Its differentiation lies in being a specialized, potentially more agile platform focused on seamless integration with next-generation PFA catheters from multiple manufacturers, as opposed to the closed ecosystems often promoted by incumbents.